– IRELAND, Dublin – Mallinckrodt plc, a global specialty pharmaceutical company, announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain, and Wesley Wheeler to its Board of Directors immediately.
Mr. Bisaro has also been reappointed to his previous role as Board Chair.
Concurrently, the Company announced that Siggi Olafsson will be President and CEO and a member of the Board.
“We are thrilled to welcome back Paul as Board Chair. He brings deep familiarity with our business and our team, and we know we will benefit greatly from his insights. We are equally pleased about the appointments of Katina, Abbas and Wes. Our ability to attract these accomplished directors is a testament to what we have achieved so far and the opportunities ahead for Mallinckrodt.” said CEO, Siggi Olafsson.
About Paul Bisaro
Paul Bisaro is a healthcare industry leader with more than three decades of leadership experience at generic and branded pharmaceutical companies. He served as Mallinckrodt’s Board Chair from June 2022 to November 2023. Mr. Bisaro previously served as President, CEO, and director of Impax Laboratories, Executive Chairman of Amneal Pharmaceuticals, Executive Chairman of Allergan, President and CEO of Actavis (formerly Watson Pharmaceuticals), and President, COO, and director of Barr Pharmaceuticals. Mr. Bisaro serves on the boards of Zoetis and Myriad Genetics and previously served on the boards of TherapeuticsMD and Zimmer Biomet.
Paul Bisaro said, “Mallinckrodt plays an important role addressing unmet patient needs and providing therapies with high clinical value. I am pleased to rejoin the Board and once again work alongside Siggi, the Executive Committee, as well as my colleagues on the Board of Directors, to continue this meaningful work and further improve execution and performance. We are all fully focused on unlocking Mallinckrodt’s full potential and delivering benefits to patients, employees, shareholders and all other stakeholders.”
About Katina Dorton
Katina Dorton has over 20 years of finance and healthcare experience across fundraising, mergers and acquisitions, and business development, most recently serving as CFOcompanydThera, a private biotechnology company. She previously served, as CFO of Repare Therapeutics, AVROBIO, and Inmatics and, earlier in her career, was a healthcare investment banker at Morgan Stanley and Needham. Ms. Dorton serves on the boards of Fulcrum Therapeutics and TScan Therapeutics and previously served on the boards of Pandion Therapeutics and US Ecology, among others.
About Abbas Hussain
Abbas Hussain has more than 30 years of leadership and operating experience in healthcare, most recently serving as CEO of Vifor. He previously served as GlaxoSmithKline’s Global President of Pharmaceuticals & Vaccines, and, earlier in his career, in various leadership roles at Eli Lilly and Company. Mr. Hussain also has served on the boards of Teva Pharmaceuticals, Aspen Pharmacare, Vifor, ViiV Healthcare, and Cochlear, among others.
About Wesley Wheeler
Wes Wheeler has more than 40 years of diversified leadership experience in healthcare, including business turnarounds and transformations, manufacturing, marketing, engineering, R&D, and supply chain. He is currently a Pharmaceutical Services Consultant at KKR. He previously served as President of UPS Healthcare and its subsidiary Marken LLP, CEO, President, and director of Patheon, and President of R&D and Global Manufacturing at Valeant Pharmaceuticals. Earlier in his career, he held various leadership roles at GlaxoSmithKline and ExxonMobil in engineering, marketing, and manufacturing.
About Mallinckrodt
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market, and distribute specialty pharmaceutical products and therapies. The Company’s Specialty Brands reportable segments’ areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specgenericnerics reportable segment includes specialty generic drugs and active pharmaceutical ingredients.
SOURCE www.mallinckrodt.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
